TenecteRel® (Tenecteplase) is the latest third generation tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle -1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
Tenecteplase has advantages of single bolus administration, least time for administration, highest resistance to plasminogen activator inhibitor (PAI) and high fibrin specificity.
TenecteRel® (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.
TenecteRel® (Tenecteplase) is the only fibrinolytic, which is recommended as half dose in patients > 75 years of age.
TenecteRel® (Tenecteplase) is for intravenous administration only. The dose is weight-based and should not exceed 50 mg. A single bolus dose should be administered over five seconds based on patient weight.
TenecteRel® (Tenecteplase) is available as 30, 40 and 50 mg kits. Each kit of TenecteRel® contains one Tenecteplase lyophilized vial (30/40/50 mg), sterile water for injection, one sterile disposable syringe, two needles and three alcohol swabs.